公开(公告)号：US11925688B2

公开(公告)日：2024-03-12

申请号：US17449685

申请日：2021-10-01

申请人： Thetis Pharmaceuticals LLC

发明人： Frank C. Sciavolino ,  Gary Mathias ,  Michael C. Van Zandt ,  Gunnar Erik Jagdmann, Jr. ,  Jessica J. Dworak

IPC分类号： A61K47/54 ,  A61K31/202 ,  A61K31/232 ,  A61K38/03 ,  A61K45/06 ,  A61K47/62 ,  A61P1/00 ,  A61P1/04 ,  A61P1/06 ,  A61P1/12 ,  A61P29/00 ,  C07C59/42 ,  C07C229/26 ,  C07C237/12 ,  C07C237/22

CPC分类号： A61K47/541 ,  A61K31/202 ,  A61K31/232 ,  A61K38/03 ,  A61K45/06 ,  A61K47/62 ,  A61P1/00 ,  A61P1/04 ,  A61P1/06 ,  A61P1/12 ,  A61P29/00 ,  C07C59/42 ,  C07C229/26 ,  C07C237/12 ,  C07C237/22 ,  A61K2800/00

摘要： The present invention relates to compounds of Formulas I-IV, which are salts of special lipid mediators of inflammation, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both.

公开(公告)号：US20240051997A1

公开(公告)日：2024-02-15

申请号：US18074227

申请日：2022-12-02

申请人： Arch Biosurgery, Inc.

发明人： Terrence Norchi ,  Rutledge Ellis-Behnke

IPC分类号： C07K14/00 ,  A61P29/00 ,  A61P19/02 ,  A61K9/00 ,  C07K2/00 ,  C07K7/06 ,  C07K7/08 ,  A61K9/16 ,  A61P11/06 ,  A61K38/03 ,  A61K38/10 ,  A61K38/08 ,  A61K38/16 ,  A61K38/07

CPC分类号： C07K14/001 ,  A61P29/00 ,  A61P19/02 ,  A61K9/0019 ,  A61K9/0014 ,  C07K2/00 ,  C07K7/06 ,  C07K7/08 ,  A61K9/1658 ,  A61P11/06 ,  A61K38/03 ,  A61K38/10 ,  A61K38/08 ,  A61K38/16 ,  A61K38/07 ,  A61K38/00

摘要： Self-assembling peptides or self-assembling peptidomimetics (“SAP”) can treat inflammation or inflammatory diseases, or reduce one or more symptoms of diseases and disorders associated with undesirable inflammation. Topical and injectable compositions of SAP for local administration to a site of inflammation for reduction or prevention of symptoms of inflammatory diseases and disorders are described. The compositions include one or more SAP in an amount and concentration effective to reduce or prevent one or more symptoms of undesirable inflammation. The SAP can assemble prior to or after the composition is administered. The SAP form a structure within or at the surface of the body that prevents and/or reduces symptoms associated with inflammation and other dysregulated immune processes. The peptides can assemble upon contact with bodily fluids (e.g., synovial fluid), or can be contacted with ionic solutions to initiate assembly.

公开(公告)号：US11826403B2

公开(公告)日：2023-11-28

申请号：US17074658

申请日：2020-10-20

申请人： UNIVERSITE DE STRASBOURG ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE ,  VAXINE PTY LTD

发明人： Vincent Marion ,  Nikolai Petrovsky

IPC分类号： A61K38/45 ,  G01N33/50 ,  A61K38/03 ,  A61K38/17

CPC分类号： A61K38/45 ,  A61K38/03 ,  A61K38/1709 ,  G01N33/5064 ,  G01N2333/91205 ,  G01N2500/04

摘要： The present invention relates to the identification of ALMS1 as the missing player involved in the regulation of the insulin-mediated glucose uptake through GLUT4 sorting vesicles, and to the down-regulation of ALMS1 by αPKC. Accordingly, the present invention relates to a molecule capable of preventing the binding of αPKC on ALMS1 for use for treating or preventing diabetes, in particular type 2 diabetes. In addition, the present invention relates to a method for identifying molecule capable of preventing the binding of αPKC on ALMS1.

公开(公告)号：US11787850B2

公开(公告)日：2023-10-17

申请号：US17138448

申请日：2020-12-30

申请人： Anie Philip

发明人： Anie Philip

IPC分类号： A61K38/10 ,  A61K38/16 ,  A61K38/18 ,  C07K14/495 ,  A61K38/00 ,  C07K7/00 ,  C07K14/705 ,  A61L17/00 ,  A61L24/00 ,  A61K35/36 ,  C12N15/86 ,  C12N15/87 ,  C07K14/71 ,  A61L31/16 ,  A01K67/027 ,  A61L15/44 ,  A61K38/03 ,  C07K7/08 ,  C07K14/00 ,  A61P1/16 ,  A61P17/02 ,  A61P35/00 ,  A61K9/00 ,  A61K9/70

CPC分类号： C07K14/70596 ,  A01K67/0271 ,  A61K9/006 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/0073 ,  A61K9/7038 ,  A61K35/36 ,  A61K38/00 ,  A61K38/03 ,  A61K38/10 ,  A61K38/16 ,  A61K38/1841 ,  A61L15/44 ,  A61L17/005 ,  A61L24/0015 ,  A61L31/16 ,  A61P1/16 ,  A61P17/02 ,  A61P35/00 ,  C07K7/00 ,  C07K7/08 ,  C07K14/00 ,  C07K14/495 ,  C07K14/71 ,  C12N15/86 ,  C12N15/87 ,  A61L2300/432 ,  Y02A50/30

摘要： The present invention provides peptidic TGF-β antagonists capable of inhibiting TGF-β signaling and disrupting the biochemical events that promote fibrosis and the epithelial-mesenchymal transition. The peptidic TGF-β antagonist may contain from 11 to 28 amino acid residues (for instance, may consist of from 12 to 16 amino acid residues) and may have the following structure (II):

NH2′ETWIWLDTNMG-Xaa1-Y′COOH  (II)

wherein Xaa1 is any amino acid and Y is a peptide having from 0 to 9 amino acids. The peptidic TGF-β antagonists can advantageously be used for the prevention, treatment, and/or alleviation of the symptoms of a condition associated with an increase in TGF-β activity, including fibrosis (such as fibrosis of the skin, liver, lungs, and heart, among others) and cancer (including various carcinomas, such as squamous cell carcinoma, sarcomas, and metastatic cancers).

公开(公告)号：US20230293624A1

公开(公告)日：2023-09-21

申请号：US17668744

申请日：2022-02-10

申请人： Cornell Research Foundation, Inc. ,  Institut De Recherches Cliniques De Montreal

发明人： Hazel H. Szeto ,  Peter W. Schiller ,  Kesheng Zhao

IPC分类号： A61K38/07 ,  A61K38/03 ,  C07K5/103 ,  C07K5/107 ,  C07K5/11 ,  C07K5/117

CPC分类号： A61K38/07 ,  A61K38/03 ,  C07K5/1008 ,  C07K5/1016 ,  C07K5/1019 ,  C07K5/1024

摘要： The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.

公开(公告)号：US20180360783A1

公开(公告)日：2018-12-20

申请号：US16109824

申请日：2018-08-23

申请人： Pathologica LLC

发明人： Jeremy BLITZER ,  John MCKEARN

IPC分类号： A61K31/15 ,  A61K9/00 ,  A61K31/4704 ,  A61K31/277 ,  A61K31/137 ,  A61K31/155 ,  A61K31/136 ,  A61K38/21 ,  A61K38/03 ,  A61K31/225

CPC分类号： A61K31/15 ,  A61K9/0053 ,  A61K31/136 ,  A61K31/137 ,  A61K31/155 ,  A61K31/225 ,  A61K31/277 ,  A61K31/4704 ,  A61K38/03 ,  A61K38/21 ,  A61K2300/00

摘要： Disclosed herein is a method of prevention of progression of a multiple sclerosis in a patient, comprising the administration of methylglyoxal bis(guanylhydrazone) (MGBG) to the patient in need thereof. Also disclosed herein is a method of prevention or reduction in severity of the initiation phase of autoimmune response in a patient having multiple sclerosis, comprising the administration of MGBG to the patient in need thereof.

公开(公告)号：US20180080909A1

公开(公告)日：2018-03-22

申请号：US15559428

申请日：2015-04-28

申请人： HYBIO PHARMACEUTICAL CO., LTD.

发明人： Yangming TANG ,  Gang HE ,  Guotao LI ,  Anjin TAO ,  Jiancheng YUAN

IPC分类号： G01N30/34 ,  G01N30/74 ,  G01N30/86 ,  G01N30/88 ,  G01N21/33 ,  G01N33/68 ,  B01D15/32 ,  B01D15/36 ,  A61K38/03

CPC分类号： G01N30/34 ,  A61K38/03 ,  B01D15/325 ,  B01D15/362 ,  B01D15/363 ,  C07K1/18 ,  C07K1/20 ,  C07K14/00 ,  G01N21/33 ,  G01N30/74 ,  G01N30/8631 ,  G01N30/88 ,  G01N33/6803 ,  G01N2030/8831

摘要： The present invention relates to a high performance liquid chromatography method for polypeptide mixtures. Specifically, the method including the following steps: step (1): preparing a solution of the glatiramer acetate to be tested; step (2): performing gradient elution on a sample to be tested with an anion exchange liquid chromatography, a cation exchange liquid chromatography, or a reversed-phase liquid chromatography; step (3): determining a peak area corresponding to each component of the glatiramer acetate, comparing the peak area with to a peak area of a reference substance to determine whether the content of each component of the sample to be tested is in a qualified range.

公开(公告)号：US20180028678A1

公开(公告)日：2018-02-01

申请号：US15703323

申请日：2017-09-13

申请人： CEDARS-SINAI MEDICAL CENTER

发明人： Lali K. MEDINA-KAUWE

IPC分类号： A61K31/704 ,  A61K49/00 ,  C07K14/475 ,  A61K38/08 ,  A61K38/03

CPC分类号： A61K47/64 ,  A61K31/704 ,  A61K38/03 ,  A61K38/08 ,  A61K47/61 ,  A61K49/0056 ,  C07K14/4756

摘要： The present invention relates to a complex that can be injected into the body to hone in on target cells to deliver molecules. In one embodiment, the invention provides a drug delivery system that includes components that self-assemble into one targeted conjugate. In another embodiment, the invention includes a targeted carrier protein and a nucleic acid sequence non-covalently linked to one or more drugs.

公开(公告)号：US20170216217A1

公开(公告)日：2017-08-03

申请号：US15421889

申请日：2017-02-01

申请人： I2O Pharma Ltd.

发明人： Michel Afargan ,  Dan Gelvan ,  Natalia Naraykin

IPC分类号： A61K9/50 ,  A61K47/26 ,  A61K38/03 ,  A61K9/51 ,  A61K31/513

CPC分类号： A61K9/5089 ,  A61K9/5026 ,  A61K9/5047 ,  A61K9/5123 ,  A61K9/5153 ,  A61K9/5192 ,  A61K31/513 ,  A61K38/03 ,  A61K38/26 ,  A61K38/31 ,  A61K47/26 ,  Y02A50/411

摘要： In one embodiment, the present invention provides a composition comprising a plurality of microcapsules, each comprising a shell and a core carrying an active agent selected from the group consisting of: (a) a non-hydrophilic active agent and (b) a hydrophilic active agent dissolved or suspended in an oil; wherein the shell comprises a polymeric coating, and wherein at least a portion of the microcapsules in a sample of the composition are spherical when the sample of the microcapsules is viewed in a scanning electron microscope with a magnification in the range of between ×2000 and ×50000.

公开(公告)号：US20170165236A1

公开(公告)日：2017-06-15

申请号：US15033311

申请日：2014-10-31

申请人： Celgene International II Sàrl

发明人： Esther MARTINBOROUGH ,  Marcus F. BOEHM ,  Adam Richard YEAGER ,  Junko TAMIYA, ,  Liming HUANG ,  Enugurthi BRAHMACHARY ,  Manisha MOORJANI ,  Gregg Alan TIMONY ,  Jennifer L. BROOKS ,  Robert PEACH ,  Fiona Lorraine SCOTT ,  Michael Allen HANSON

IPC分类号： A61K31/4245 ,  A61K31/225 ,  A61K31/137 ,  A61K38/03 ,  A61K39/395 ,  A61K31/427 ,  A61K38/21 ,  A61K31/454 ,  A61K31/5377 ,  A61K31/496 ,  A61K31/635 ,  A61K31/4704 ,  C07K16/28

CPC分类号： A61K31/4245 ,  A61K31/137 ,  A61K31/225 ,  A61K31/427 ,  A61K31/454 ,  A61K31/4704 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/635 ,  A61K38/03 ,  A61K38/215 ,  A61K39/39541 ,  A61K2039/505 ,  C07K16/2839 ,  C07K16/2866 ,  C07K16/2887 ,  C07K16/2893 ,  C07K2317/24 ,  A61K2300/00

摘要： Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided, including compounds which modulate subtype 1 of the S1P receptor, and methods of their therapeutic and/or prophylactic use in combination with at least one other medicament adapted for treatment of a malcondition for which activation of S1P1 is medically indicated, such as multiple sclerosis.